This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
KiOR: Catalyzing Clean Energy
Nanda, Ramana; Stuart, TobyCase HBS-809092-EEntrepreneurshipBiofuels start-up KiOR was developing a proprietary technology that had the potential to dramatically impact the emerging renewable energy landscape: a process that converted cellulosic biomass into "bio-crude," a hydrocarbon mixture with properties to those of crude oil. KiOR had been operating as a virtual organization, but with venture financing in place, founder and chief technology officer Paul O'Connor and the KiOR board needed to decide wh...Starting at €8.20
-
Tennant Company
Stuart, Toby; Applegate, Lynda M.; Weber, JamesCase HBS-810040-EEntrepreneurshipTennant, a leading producer of floor cleaning equipment, must determine how to create, finance, structure, staff, govern, measure and manage a new venture for developing a fundamentally new product line. In 2005, Tennant Company had developed an innovative, environmentally friendly, cleaning technology that could potentially revolutionize cleaning. Historically, Tennant was a producer of floor and carpet washing machines for industrial and commer...Starting at €8.20
-
Sirtris Pharmaceuticals: Living Healthier, Longer (Abridged)
Stuart, Toby; Webber, JamesCase HBS-813029-EEntrepreneurshipDescribes a set of key strategic decisions facing the scientific founder and CEO of a promising, early stage bio-pharmaceuticals company. Should the company establish a proposed alliance with a pharmaceutical firm? Should it create a nutraceuticals business in parallel to its effort to develop anti-aging therapeutics? And, should it in-license a second drug development candidate?Starting at €8.20
-
Sirtris Pharmaceuticals: Living Healthier, Longer
Stuart, Toby; Kiron, DavidCase HBS-808112-EEntrepreneurshipDescribes a set of key strategic decisions facing the scientific founder and CEO of a promising, Early stage bio-pharmaceuticals company.l Should the company establish a proposed alliance with a pharmaceutical firm? Should it create a nutraceuticals business in parallel to its effort to develop anti-aging therapeutics? And, should it in-license a second drug development candidate?Starting at €8.20
-
GSK's Acquisition of Sirtris: Independence or Integration, Teaching Note
Stuart, TobyTeaching Note HBS-811012-EEntrepreneurshipTeaching Note for 809026.Starting at €0.00
-
Non-Equity Financing for Entrepreneurial Ventures
Farre-Mensa, Joan; Nanda, Ramana; Jain, PiyushCase HBS-814005-EEntrepreneurshipYoung, and particularly high-growth ventures often need to raise significant external finance, since their internal cash flow is usually insufficient to support the investments needed to grow. Although raising equity from venture capital or angel investors is the most well-known source of external finance for high-growth ventures, many entrepreneurs, particularly small business owners, rely on debt and other non-equity sources of capital to finan...Starting at €8.20
-
Entrepreneurial Finance Lab: Scaling an Innovative Start-up Financing Venture
Farre-Mensa, Joan; Kerr, William R.; Brownell, AlexisCase HBS-814073-EEntrepreneurshipEFL provides credit-scoring services in developing countries using psychometric assessment, but the potential loss of a large customer makes them reconsider their scaling narrative.Starting at €8.20
-
Entrepreneurial Finance Lab: Scaling an Innovative Start-up Financing Venture, Teaching Note
Farre-Mensa, JoanTeaching Note HBS-815064-EEntrepreneurshipTeaching note for case 814073.Starting at €0.00
-
Entrepreneurial Finance Lab: A Founding Story (A)
Ghosh, Shikhar; Farre-Mensa, Joan; Payton, ChristopherCase HBS-815119-EEntrepreneurshipStarting at €8.20
-
GSK's Acquisition of Sirtris: Independence or Integration
Stuart, Toby; Weber, JamesCase HBS-809026-EEntrepreneurshipAn executive from pharmaceutical company GSK must choose how much to integrate a recently acquired biotechnology firm, Sirtris. Moncef Slaoui, GSK's Global head of R&D, championed the acquisition of Sirtris to gain access to its potentially revolutionary science. Slaoui must balance the need to recoup shareholder value after paying a two-times premium for Sirtris with his desire to retain Christoph Westphal, Sirtris's co-founder and CEO, and othe...Starting at €8.20